摘要
目的探讨门冬胰岛素在治疗妊娠期糖尿病孕妇（GDM）的疗效。方法经医院伦理委员会审核通过，孕妇自愿签署统一的知情同意书。将需要胰岛素治疗的GDM孕妇按1：1配对，共80例孕妇，分为门冬胰岛素组和生物合成人胰岛素组各40例，比较两组第1、3、5天3餐餐后2h血糖以及母婴结局。结果两组孕妇比较使用胰岛素治疗后第1、3、5天3餐后2h血糖，仅第3天早餐后2h血糖门冬胰岛素组（6．9±0．9）mmol／L，生物合成胰岛素组（7．54-1．4）mmol／L，两组比较差异有统计学意义，P〈0．05．两组孕妇胰岛素用量、血糖达标时间、分娩孕周等差异无统计学意义，P〉0．05，孕妇满意度门冬胰岛素组87．5％，生物合成人胰岛素组75％，差异有统计学意义，P〈0．01。两组孕妇并发症及新生儿结局差异均无统计学意义（均P〉0．05）。结论门冬胰岛素治疗GDM孕妇安全有效。
Objective To explore the efficacy and safety of human aspart versus regular human insulin in women with gestational diabetes mellitus （ GDM）. Methods A total of 80 women with GDM during pregnancy delivered at our hospital divided into 2 groups ： Group 1 with human aspart and regular human insulin N while Group 2 with regular human insulin R and N. The levels of glucose were compared before and after 2 h at breakfast, lunch and supper at Day 1, 3 and 5. And the outcomes of women and their babies were evaluated. Results No significant difference in general characteristics existed between two groups. Except for breakfast of Day 3, no significant difference was found in terms of the amount of insulin, the time of satisfactory glucose level and delivery time point, etc. There was no significant inter-group difference in the outcomes of pregnant women and their babies. Conclusion The efficacy and safety of human aspart or regular human insulin are comparable for the women with gestational diabetes mellitus.
出处
《中华医学杂志》
CAS
CSCD
北大核心
2012年第19期1334-1336,共3页
National Medical Journal of China
基金
首都医学发展科研基金（2009-3245）
关键词
门冬胰岛素
妊娠期糖尿病
治疗
Insulin aspart
Gestational diabetes
Mellitus therapy
